Samsung Biologics Co. Ltd.
Samsung Biologics Co. Ltd.
01/19/2026 | Press release | Distributed by Public on 01/19/2026 22:37
Seamless technology transfer: Accelerating biologics from drug substance to drug product
UPDATE |January 20, 2026
Seamless technology transfer: Accelerating biologics from drug substance to drug product
- COPY
Samsung Biologics has supported biologics developers for more than a decade, building a reputation as a reliable CDMO partner that reduces operational complexity, accelerates regulatory pathways, and helps deliver therapies to patients worldwide.
Our end-to-end tech transfer framework standardizes workflows and embeds right-first-time principles into every project, helping clients advance their programs efficiently while maintaining high product quality and regulatory confidence.
Our end-to-end tech transfer framework standardizes workflows and embeds right-first-time principles into every project, helping clients advance their programs efficiently while maintaining high product quality and regulatory confidence.
Samsung Biologics has supported biologics developers for more than a decade, building a reputation as a reliable CDMO partner that reduces operational complexity, accelerates regulatory pathways, and helps deliver therapies to patients worldwide.
Our end-to-end tech transfer framework standardizes workflows and embeds right-first-time principles into every project, helping clients advance their programs efficiently while maintaining high product quality and regulatory confidence.
Attached
- Seamless technology transfer: Accelerating biologics from drug substance to drug product
Related Content
Samsung Biologics Co. Ltd. published this content on January 19, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on January 20, 2026 at 04:37 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]